IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
批准号:
3151971
负责人:
DAVID A HORWITZ
金额:
$14.76万
依托单位国家:
美国
项目类别:
财政年份:
1980
资助国家:
美国
项目状态:
已结题
起止时间:
1980-09-01 至 1986-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The long-term objective of this proposal is to develop a greater understanding
of the cellular components which mediate and regulate the human immune response.
We plan to identify, characterize and look for abnormalities of newly described
subsets of mononuclear cells found in the blood and tissues of patients with
rheumatic diseases. We will continue to study "L" cells, a presumptive subset
of non-T, non-B cells with high avidity Fc receptors for IgC. The precise
relationship of L cells with other mononuclear cells will be investigated by
characterizing cell surface antigens on L cells and other mononuclear cells with
monoclonal antibodies produced by hybridomas. Flow cytofluorography will be
utilized to accomplish this task. Secondly, specific cell-types will be
separated on the basis of cell surface markers by cell-sorting and the
functional properties of purified cells will be compared using in vitro
techniques. We will investigate L cells-T cells interactions in the regulation
of B cell function. Thirdly, L cells are excellent mediators of spontaneous or
natural killer antibody-dependent cellular cytotoxicity. A comparison of the
cytotoxic effects of L cells with other cell types will be continued. Finally,
we plan to learn the significance of a cellular cytotoxicity defect we have
recently described in rheumatoid arthritis. Studies will be conducted to define
the effector cells and regulatory cells involved in this defect, to learn
whether this defect may be an important pathogenetic factor in rheumatoid
arthritis and to investigate possible means of correcting this defect. It is
likely that a better understanding of regulatory abnormalities in patients with
rheumatic diseases will lead to new and safer approaches to control these
disorders.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Studies on human blood lymphocytes with iC3b (type 3) complement receptors. I. Granular, Fc-IgG receptor positive and negative subsets in healthy subjects and patients with systemic lupus erythematosus.
对带有 iC3b(3 型)补体受体的人血淋巴细胞的研究。
DOI:
--
发表时间:
1986
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Bakke,AC, Gray,JD, Abo,W, QuismorioJr,FP, Lash,A, Cooper,SM, Horwitz,DA]
通讯作者:
Horwitz,DA
Studies on human blood lymphocytes with iC3b (type 3) complement receptors: III. Abnormalities in patients with active systemic lupus erythematosus.
具有 iC3b(3 型)补体受体的人血淋巴细胞的研究:III。
DOI:
--
发表时间:
1987
期刊:
Clinical and experimental immunology
影响因子:
4.6
作者:
[Gray,JD, Lash,A, Bakke,AC, Kitridou,RC, Horwitz,DA]
通讯作者:
Horwitz,DA
DOI:
10.4049/jimmunol.129.6.2519
发表时间:
1982-12
期刊:
Journal of immunology
影响因子:
4.4
作者:
[K. Nishiya;D. Horwitz]
通讯作者:
K. Nishiya;D. Horwitz
Characterization oflymphocytes that suppress IL-2production in systemic lupuserythematosus
系统性红斑狼疮中抑制 IL-2 产生的淋巴细胞的特性
DOI:
--
发表时间:
1988
期刊:
影响因子:
--
作者:
[M. Linker‐Israeli]
通讯作者:
M. Linker‐Israeli
Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.
表达 3 型补体受体的淋巴细胞响应白细胞介素 2 进行增殖,并且是淋巴因子激活的杀伤细胞的前体。
DOI:
10.1172/jci113442
发表时间:
1988
期刊:
The Journal of clinical investigation
影响因子:
--
作者:
[Gray,JD, Horwitz,DA]
通讯作者:
Horwitz,DA
共 12 条
Nanoimmunotherapy for chronic immune-mediated diseases
-
批准号:10483819
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2022
-
负责人:DAVID A HORWITZ
-
依托单位:
Flow Cytometry and Immune Monitoring Core
-
批准号:7302498
-
项目类别:
-
资助金额:$4.22万
-
财政年份:2006
-
负责人:DAVID A HORWITZ
-
依托单位:
Flow Cytometer
-
批准号:6441078
-
项目类别:
-
资助金额:$48.44万
-
财政年份:2002
-
负责人:DAVID A HORWITZ
-
依托单位:
CORE--FLOW CYTOMETRY
-
批准号:6300004
-
项目类别:
-
资助金额:$27.55万
-
财政年份:1999
-
负责人:DAVID A HORWITZ
-
依托单位:
CORE--FLOW CYTOMETRY
-
批准号:6101571
-
项目类别:
-
资助金额:$27.55万
-
财政年份:1999
-
负责人:DAVID A HORWITZ
-
依托单位:
CORE--FLOW CYTOMETRY
-
批准号:6295813
-
项目类别:
-
资助金额:$27.55万
-
财政年份:1998
-
负责人:DAVID A HORWITZ
-
依托单位:
CORE--FLOW CYTOMETRY
-
批准号:6268712
-
项目类别:
-
资助金额:$26.25万
-
财政年份:1997
-
负责人:DAVID A HORWITZ
-
依托单位:
CORE--FLOW CYTOMETRY
-
批准号:6236112
-
项目类别:
-
资助金额:$26.32万
-
财政年份:1996
-
负责人:DAVID A HORWITZ
-
依托单位:
FLUORESCENT ACTIVATED CELL SORTER UPGRADE SYSTEM
-
批准号:3520070
-
项目类别:
-
资助金额:$12.9万
-
财政年份:1988
-
负责人:DAVID A HORWITZ
-
依托单位:
IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
-
批准号:2882234
-
项目类别:
-
资助金额:$25.56万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
-
批准号:3155704
-
项目类别:
-
资助金额:$16.12万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
Immunoregulatory Mechanisms in the Rheumatic Disease
-
批准号:6400460
-
项目类别:
-
资助金额:$30.91万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
Immunoregulatory Mechanisms in the Rheumatic Disease
-
批准号:6631975
-
项目类别:
-
资助金额:$32.5万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
-
批准号:2667790
-
项目类别:
-
资助金额:$23.46万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
IMMUOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
-
批准号:3155711
-
项目类别:
-
资助金额:$19.8万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
IMMUOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
-
批准号:3155709
-
项目类别:
-
资助金额:$18.17万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
Immunoregulatory Mechanisms in the Rheumatic Disease
-
批准号:6875645
-
项目类别:
-
资助金额:$32.5万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
IMMUOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
-
批准号:2078662
-
项目类别:
-
资助金额:$20.52万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
IMMUNOREGULATORY MECHANISMS IN THE RHEUMATIC DISEASES
-
批准号:3155707
-
项目类别:
-
资助金额:$16.71万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
Immunoregulatory Mechanisms in the Rheumatic Disease
-
批准号:6510747
-
项目类别:
-
资助金额:$32.5万
-
财政年份:1980
-
负责人:DAVID A HORWITZ
-
依托单位:
海外基金